Currently Only Enrolling Glioblastoma Patients at First Recurrence Clinical Trials in Stanford, California

Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas